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Abstract. In Nigeria, the Lassa Fever outbreak of 2015 
had been persistent up till the present (end of 2019), with 
significant mortality and morbidity. The epidemiology 
of Lassa Fever is gradually changing towards assuming 
an endemic dimension despite several evidence-based 
efforts taken by stakeholders towards disease control. 
Several challenges militate against prevention and 
control efforts. These are related to environmental and 
climatic factors, poor knowledge risk perception and 
preventive practices among community members and 
health care workers, poor diagnosis and treatments of 
the disease. It is doubtful that Nigeria could successfully 
win the war against Lassa Fever without surmounting 
the challenges identified in this review article. The 
efforts to curtail Lassa Fever would yield significant 
reduction in prevalence if these challenges militating 
against prevention and control are removed. This would 
require collaborative efforts among all stakeholders that 
are relevant to this task, and Governments creating an 
enabling environment for prevention and control efforts 
to thrive.
Keywords: Lassa Fever, Nigeria, Disease control, 
Challenges, Surveillance, Prevention
1. Introduction
In 2014, Nigeria experienced the most devastating 
outbreak of acute viral hemorrhagic fever (AVHF) notably 
the Ebola virus outbreak. The coordinated response of the 
health system led to the containment of this Ebola virus 
disease outbreak. However, the Lassa Fever (LF) outbreak 
of 2015 had been persistent up till the present, and it is 
a test of how the country and indeed the West African 
sub-region could fill disease control gaps and respond 
to emerging health issues. The Lassa virus is now a 
problem of high public health importance, especially as 
it causes significant mortality and morbidity, and exerts 
pressure and undue impact on the public health system 
(Mofolorunsho, 2016; NCDC, 2017; Tambo, Ugwu and 
Ngogang, 2014). Other prevalent examples of the diverse 
mild to a severe group of animal and human illnesses 
categorized as AVHF include yellow fever and dengue 
(dengue haemorrhagic fever).
Lassa Fever is caused by the Lassa Fever virus (LASV) 
which is a member of the Arenaviridae family. It is a 
zoonotic acute viral haemorrhagic disease of humans, 
which is endemic in West African countries including 
Sierra Leone, Guinea, Benin Republic, Côte d’Ivoire, 
Mali, Liberia and Nigeria, where a significant outbreak is 
ongoing and persistent for some years now. LF was first 
isolated in 1969 among two infected missionary nurses 
who eventually died in the town of Lassa in Nigeria 
(Adewuyi, Fowotade and Adewuyi, 2009; Mylne et al., 
2015). Figure 1 shows the distribution of Lassa Fever in 
Nigeria between 2015-2019 (NCDC, 2019).
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Within an incubation period ranging from six (6) days 
to twenty-one (21) days, the single stranded RNA type 
LASV finds convenient reservoir in a transmitting rodent 
vector (the Mastomys natalensis) which has adapted to a 
peri-domestic life in village houses in West Africa (WHO, 
2007). Lassa Fever transmission is essentially through 
contact with infected rodent’s faeces, saliva or urine, 
inhaling contaminated dust, eating contaminated food 
or by contact with bodily fluids of an infected person 
dead or alive (human-to-human transmission) (WHO, 
2010; Ilori, Furuse and Ipadeola, 2019; Ogoina , 2015). The 
ongoing epidemic predominantly affects three states of 
Ondo, Edo and Ebonyin which include 4.6% of Nigeria’s 
population, yet accounts for 74.6% of the increase in 
confirmed cases during the 2017 and 2018 peak seasons 
(NCDC, 2018). In Nigeria, the average case fatality (CF) 
among patients with confirmed LF declined from 154/355 
(43%) in 2001, to 183/867 (21.1%), and the decline was found 
to be statistically significant (p < 0.001). The annual CF 
declined from 94% in 2001 to 15% in 2018 whereas the 
caseload increased from 0.3% to 3.4% (Akpede, Asogun 
and Okogbenin, 2019). The observed case-fatality rate 
(CFR) among patients hospitalised for severe LF is 15%–
50% (WHO, 2019; CDC, 2018). Figure 2 shows the number 
of cases reported on a yearly basis between 2016 and 2019 
(NCDC, 2019).
From 1st January 2019 to 10th November 2019 (NCDC, 
2019), a total of 4500 suspected cases have been reported 
from 23 states in Nigeria. Of these, 764 were confirmed 
positive, 19 probable and 3717 negative. There have been 
160 deaths in confirmed cases. The predominant affected 
age-group is between 21-40 years (Range: >1 month to 98 
years, median age: 34 years), and the male to female ratio 
for confirmed cases is 1:1. As many as 90% confirmed 
cases have been linked to circumstances such as new 
agricultural practices (Kafetzopoulou, 2019), yet the 
role of data on rodent abundance are not available, and 
need to be determined. An understanding of the genus 
is also important to ascertain which species and exact 
subspecies act as a virus reservoir (Safronetz, 2015). Figure 
3 shows the number of confirmed cases of Lassa fever 
in 2019 as reported by the Nigerian Center for Disease 
Control (NCDC, 2019).
2. Review Methodology
The focus of this review is on Lassa Fever in the African 
continent with special focus on Nigeria, and to explore 
reported challenges facing the control of the outbreak in 
Nigeria: a scenario that has persisted for quite some time 
in the country. There was no limitation to the number of 
Lassa Fever cases in an eligible published review article 
and no restriction on its contents. Articles were identified 
by electronic searches of popular databases such as 
PubMed, CINAHL, Web of Science, MEDLINE, EMBASE, 
the Cochrane Central, Scopus, and Google Scholar. 
Additional pertinent citations were identified through 
bibliographies of retrieved studies. Authors were able to 
screen articles to narrow them down to those touching 
on the challenges facing the containment of the outbreak 
using relevant keywords such as Lassa Fever and Nigeria. 
A literature search strategy was developed by one of the 
authors, with the help of a University library staff who 
had expertise in literature search.
All data bases available on the internet were visited, 
with a rigorous search for studies that were published 
up to December 2020. The search strategy used a 
combination of Medical Subject Headings (MeSH terms) 
and keywords to capture Lassa Fever. All study designs 
were considered for inclusion. There were no language 
restrictions. Authors could not conduct a meta-analysis 
because the number of studies for each of the selected 
categories of challenges was not enough to pool together 
meaningful data, thus this is a review article.
3. Challenges curtailing the control of 
Lassa fever in Nigeria
The five challenges of curtailing the outbreak and spread 
of Lassa fever in Nigeria are:
1. The changing epidemiological patterns and risk 
factors associated with Lassa Fever,
2. Environmental and climatic factors affecting the 
transmission of Lassa Fever,
3. The clinical presentation and diagnosis of Lassa Fever,
4. Treatment of Lassa Fever,
5. Prevention of Lassa Fever.
Challenges associated with changing 
epidemiological patterns and risk 
factors associated with Lassa Fever:
Despite the continued threats posed by LASV, 
comprehensive data on prevalence and pattern are 
lacking. The huge population of Nigeria could make 
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disease surveillance and contact tracing a challenging 
task. If rodents are present in a highly dense population, 
the number of cases may increase exponentially. Many 
reports on Lassa Fever are pockets of specific hospital 
based data conducted by researchers which may not 
be generalisable to the general population (Ogbu, 
Ajuluchukwu and Uneke, 2007; Fichet-Calvet and 
Rogers, 2009).
Community knowledge about Lassa Fever is poor, 
though awareness may be high. This pattern could brew 
a poor risk perception to the disease, poor attitude and 
poor disease preventive practices (Ogboghodo, 2019; 
Olowookere, 2017; Sagir and Ahmed, 2019; Gobri, 2019; 
Adebimpe, 2015a; Olayinka et al., 2015; Reuben and Gyar, 
2016). Improving community awareness about Lassa 
Fever would assist to take precautions on animal to 
human transmission, hygiene practices and good health 
seeking behaviour related to Lassa Fever epidemiology 
(Adebimpe, 2015a).
Good knowledge among health care workers is not 
significantly high, is associated with poor risk perception 
and poor practices of universal precaution and infection 
control. When health care workers are familiar with the 
epidemiology of Lassa Fever and become proficient in 
clinical diagnosis, then under recognition and under 
reporting will greatly reduce and the disease would attract 
the desired attention (Adebayo et al., 2015; Aigbiremolen 
et al., 2012; Ijarotimi et al., 2018). It is therefore important 
that formal training, on-the-job and refresher training 
be organised for health care workers at all levels of care, 
to improve their knowledge base and reinforce early 
detection and reporting of cases.
The health system may use the opportunity created 
by social media and digital cloud-sourcing to develop 
timely risk communication and reporting systems that 
would create awareness among the general population. 
The advent of consumer/provider-generated mHealth 
technology can also compliment efforts to reach out to 
the general community, and this is not difficult in Nigeria 
where mobile phone technology is readily accessible 
(Giles and Adams, 2015). The possibility of nosocomial 
transmission of Lassa Fever virus points to the dire need 
to increase community and health care knowledge, risk 
perception and preventive practices against Lassa Fever.
Challenges associated with 
environmental and climatic factors 
affecting the transmission of Lassa 
fever:
The proliferation of rodents, most especially in the early 
rainy season is central to animal-human Lassa Fever 
transmission. There are several community practices 
that encourage Lassa Fever transmission such as crowded 
living rooms and houses, not having a specific space for 
a store, open storage of raw foods, sun drying of food 
under processing and poor attitude to rodent control 
(Mari Saez et al., 2018; Tobin et al., 2015; Swanepoel et al., 
2017; Parsons et al., 2017; Salmón-Mulanovich et al., 2016; 
Aigbiremolen et al., 2012; Abubakar et al., 2018). In a study 
by Giles and Adams, (2015), 96.1% of houses had seen 
rodents in the previous 6 months. Rural urban drift is 
common in Nigeria as people tend to afford the benefits 
of urbanisation, and would only worsen the present 
situation about transmission. Thus it is important that 
all households strive to keep rodents out of homes and 
food supplies as well as observing proper personal and 
environmental hygiene (Adewuyi et al.,2009).
Communities may decide to adopt a cultural approach 
to refuse management by hosting large dump of refuse 
within traditional settlements before eventual transfer to 
a public dumping site. This could be made worse when 
communities depend on the Government bringing 
trucks to come and evacuate refuse at community level. 
Such prolonged stay of refuse near habitable houses 
could facilitate breeding of rodents and proliferation and 
spread of Lassa fever. Poor community practices towards 
rodent control has been documented by several studies 
(Bonner et al., 2007; Awosanya, 2018). It is therefore 
important for stakeholders to improve community 
awareness on rodent control, and a need to develop local 
culturally effective and acceptable design measures that 
could lead to the elimination of infectious rodents (Giles 
and Adams, 2015).
In the absence of preventive medication or vaccine 
against Lassa Fever, increasing community awareness and 
health education to avoid contact with reservoir sources 
mainly rats is important. Environmental related measures 
that stakeholders in Lassa fever control could take include 
prevention of food infestation by rodents, most especially 
at night, food safety practice and appropriate waste 
management, improved water, sanitation and hygiene 
(WASH) program implementation, controlled mass 
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movements and urbanisation, and wildlife management 
and risk reduction for zoonotic diseases.
Climatic factors are also an important determinant 
of Lassa Fever transmission. In a study to analyse the 
surveillance-based incidence data of LF in Nigeria from 
2016 to 2018 (Shehu et al., 2018), two different (high- 
and low-) risk periods of Lassa Fever transmission were 
observed. The high-risk period spanned from the last 
month of the year to the second to third month of the 
new year. The relative risk of acquiring LF infection 
during the high-risk period was five times greater than 
during the rest of the year, possibly indicating that the 
rainfall pattern was highly and negatively correlated 
with LF incidence.
During dry season (as rain ceases in late November), 
scarcity of food on the ground, force mature rodents to 
migrate towards human occupied areas or communities, 
to breed, thereby supporting a higher probability of 
acquiring LF infection. This high-exposure frequency 
persists until the rainy season starts again the following 
year, at which point the rodents migrate back to the 
ground and a subsequent decline in human cases 
of Lassa Fever are observed. This seasonal ecology 
of the animal host (Marie et al., 2018) could explain 
the seasonality of LF epidemics. This supports the 
conclusion that the rainfall pattern was the main single 
abiotic factor contributing to Lassa Fever (Fichet-
Calvet, 2009). A strategic design of preventive measures 
that could contain seasonal epidemics of LF to raise 
awareness among local residents and disrupt seasonal 
movements of rodents is recommended. There is a need 
for stakeholders to prioritise a “One Health” approach 
technology to strengthen bilateral health systems of 
animal and humans towards disease control (WHO, 
2007; WHO, 2000).
Challenges associated with clinical 
presentation and diagnosis of Lassa 
Fever:
The clinical presentation of Lassa Fever mimics that of 
several other febrile illnesses endemic in West Africa, 
thus making it difficult to differentiate and diagnose and 
could lead to late presentation and appropriate treatment 
(Mertens et al., 1973). A low index of suspicion among 
clinicians has been reported as Lassa Fever is often 
considered only after patients have been presumptively 
treated for malaria and typhoid fever, without 
improvement (McCormick, 1987).
The clinical presentation of LF varies from 
asymptomatic or mild illnesses in the majority (80%) of 
infections (Richmond and Baglole, 2003). Symptomatic 
cases usually present with fever, weakness, and general 
malaise, with headache, sore throat, muscle pain, chest 
pain, nausea, vomiting, diarrhea, cough, and abdominal 
pain after a few days (Bausch, 2014; Abdulraheem, 2012), 
followed by commonly observed complications such 
as bleeding, facial oedema, convulsions, pericardial 
effusions and coma (Ehichioya et al., 2012). Diagnostic 
proficiency of Lassa Fever among health care workers was 
generally poor (Shaffer et al., 2014; Mazzola and Kelly-
Cirino, 2019) and could be a reason for late presentation. 
Most cases appear mild or even asymptomatic and could 
call for a high index of suspicion among health care 
workers
Frequent confusion of Lassa Fever with other febrile 
illnesses calls for a dire need for reliable laboratory 
diagnostic tests for early confirmation, initiation 
of healthcare barrier precautions, patient isolation, 
treatment and contact tracing. Though knowledge 
on Lassa Fever in Nigeria is high among medical 
practitioners, poor access to affordable and simple tests for 
timely diagnosis and confirmation of Lassa Fever cases is 
one of the challenges facing Lassa Fever management in 
Nigeria (Idemyor, 2010). Despite this, it was reported (Eze 
et al., 2010) that Nigeria has four documented episodes 
of Lassa Fever occurrences as nosocomial transmissions. 
In the absence of a reliable diagnosis, conflicting data 
reporting may occur most especially among subclinical 
cases.
The World Health Organization (WHO) has 
recommended the establishment of Centres of Excellence 
for prompt and effective diagnosis of Lassa Fever in 
all affected countries ((WHO, 2019). The West Africa 
sub region accounts for a high Lassa Fever endemicity 
and outbreaks (Sogoba et al., 2012; Gibbs et al., 2017), 
however, there have been only two of such centres 
with recommended biosafety levels (BSL) ranging from 
1 to 4 as classified by the World Health Organization 
(Olayiwola and Bakarey, 2017). Such centeres include the 
one at Kenema General Hospital, Sierra Leone (Khan et 
al., 2008), and the Institute of Lassa Fever Research and 
Control, ILFR&C at Irrua Specialist Teaching Hospital 
(ISTH), Nigeria (Asogun et al., 2012). The bases for the 
laboratories classification include the laboratory design, 
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Figure 1: Distribution of Lassa Fever in Nigeria between 2015-2019. (Source: NCDC, 2019) 
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Figure 2: Number of cases of Lassa fever between 2016-2019 (Source: NCDC, 2019): 
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availability of containment facility, and handling of 
biological agents (WHO, 2015).
Reliable methods of Lassa fever diagnosis are:
1. Viral antigens detection,
2. Nucleic acids, and IgM/IgG antibodies detection,
3. Reverse transcription polymerase chain reaction 
(RT-PCR): which is the gold standard, good in early 
detection, and in rapid and mobile diagnosis (Grove, 
2011; Panning, 2010),
4. Enzyme-linked immune-sorbent serologic 
assays (ELISA): which may be good for secondary 
confirmation (Panning, 2010),
5. Tissue culture,
6. Postmortem diagnosis through 
immunohistochemistry from formalin-fixed tissues 
(Panning, 2010).
Challenges associated with treatment 
of Lassa Fever:
Like several other VHFS, there is no vaccine for the 
prevention of Lassa Fever as at present (Lukashevich, 
2012). Efforts had been targeted on treatment and 
supportive care. Ribavirin (1-b-d-ribofuranosyl-1,2,4-
triazole-3-carboxamide), is a guanosine analogue, and 
was found to be active against a broad spectrum of DNA 
and RNA viruses (Bausch, 2010; NCDC, 2018). This is 
based on a single clinical trial successfully carried out in 
Sierra Leone in 1986 by McCormick et al. Its effectiveness 
is best within six days of administration. While its mode 
of action is none-specific, it has numerous adverse 
treatment outcomes (Chew, 2009). Its mode of action 
in viral replication (Bausch, 2010; Oestereich, 2016) is 
however unclear.
Rivabirin is currently the recommended medication 
for Lassa Fever (NCDC, 2019; Bossi et al., 2004). Its 
therapeutic potentials either as a single drug or in 
combination therapy is doubtful in some quarters, costly 
and contraindicated in pregnancy. Common side effects 
of ribavirin include hemolytic anaemia and infusion-
related reactions such as rigors. To confirm efficacy of 
Ribavirin, a study (Okokhere et al., 2018) at the Irrua 
Specialist Teaching Hospital was carried out between 
January 2011 and December 2015, where a total of 291 
treated patients were investigated. Overall case-fatality 
rate (CFR) was 24% (68 out of 284 patients).
Other studies on case fatalities during the 2016 
outbreak in Nigeria reported 59.6% among 47 confirmed 
cases (Buba et al., 2018), 36% among 11 confirmed cases 
(Shehu et al., 2018) and 60% among 57 confirmed cases 
reported by ECDC (ECDC, 2016). Probable reasons for 
high CFR include late presentation in the hospital 
(McCormick et al., 1986), late diagnosis (Fidelis and 
Olajolumo, 2018), poor capacity of human and material 
resources, shortage of ribavirin, low index of suspicion 
among clinicians, lack of access to ribavirin and poor 
treatment compliance (Houlihan, 2017).
The susceptibility of healthcare workers at risk of 
infection from Lassa Fever patients increases when 
adherence to infection prevention and control is poor 
(Richmond and Baglole, 2003; Fidelis and Olajolumo, 
2018). Unfortunately, there has been no substantial 
change in the case-fatality rate over the past 3 years. It 
is thus important to familiarise healthcare workers with 
the new WHO treatment guidelines, build their capacity 
to reduce nosocomial transmission and help them to 
better detect and treat Lassa virus earlier 3.5.
Challenges associated with prevention 
of Lassa Fever:
To prevent Lassa Fever, a strong health care system that 
would integrate a good surveillance system, improve 
stakeholders and community knowledge, reduce 
exposures to transmission foci, and coordinated by 
a strong preparedness and response team would be 
required. Several vaccine trials against Lassa Fever has 
not been remarkable including a Nigerian trial (Hallam 
et al., 2018), with the most promising candidates to date 
being the ML2 (Lukashevich, 2012).
Major efforts should be to prioritise disease 
prevention. Essentially, Lassa Fever prevention includes 
the promotion of good community hygiene to discourage 
rodents from entering homes, sustained good infection 
prevention and control practices among health care 
workers, while people or community should practice 
the use of rodent-proof containers to store food and 
keeping their homes clean to deter rodents. Prevention 
of transmission of the virus in hospital settings 
include: wearing protective equipment around infected 
individuals such as masks, gloves, gowns, and goggles 
and other hygienic techniques (Houlihan, 2017).
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4. Recommendations
The following six-point agenda for effective 
prevention of Lassa Fever in Nigeria are recommended:
Sustained awareness creation on 
Lassa Fever targeted at the general 
population.
There is a need to improve risk communication and social 
mobilisation on all matters related to Lassa Fever control 
to break the chain of the ongoing outbreak (Sumo et al., 
2019; Gillespie et al., 2016).
To repress the spread of Lassa Fever and help prevent 
the zoonotic transmission of the virus (Olayinka et al., 
2015), people should practice the use of rodent-proof 
containers to store food and keep their homes clean to 
deter rodents.
Building and strengthening 
interdisciplinary teams to cover 
preventive and control measures.
This should include setting up an emergency response 
team and a national body to coordinate Lassa Fever 
response, institutionalising a standard operating 
procedure related to diagnosis and treatment and 
galvanising NGO support for Lassa Fever prevention 
through awareness creation are steps in the right 
direction taken by Nigeria.
Gathering strong political support 
for Lassa Fever management and 
prevention.
Currently, diagnosis of LASV is achieved through support 
from international donors. There is a need to remove 
barriers of transportation logistics for specimens, and 
address the issue of poor quality of samples submitted to 
the reference laboratories as well as improve laboratory 
networks.
Improved funding through budgetary 
allocation.
For surveillance, prompt case management include 
laboratory facilities, training of health personnel, isolation of 
cases, barrier nursing, contact tracing, provision of antiviral 
drugs and vaccines development. Lassa Fever management 
in Nigeria is still largely donor dependent.
Strengthening Lassa fever 
epidemiologic risks surveillance and 
early laboratory detection.
Improving the diagnostic proficiency of health works 
both in terms of clinical and laboratory diagnosis is 
important. Bleeding which is a characteristic symptom 
may not show in more than 20% of cases, thus a need 
for high index of suspicion among health care workers. 
Most patients present at a late stage of the disease, also 
stressing the importance of effective case management 
and the use of personal protective equipment to improve 
diagnostic proficiency (Olowookere et al., 2017).
Enhanced active surveillance activities targeting 
Lassa Fever: timely and complete reporting of all 
probable, suspected and confirmed cases of Lassa 
Fever, contact tracking and outbreak investigations 
would assist in watching over the course of the disease 
and taking preventive actions through regular data 
collection. Surveillance activities carried out by Nigerian 
Government in the ongoing outbreak include:
1. Increase in number of reference laboratories,
2. Improved sample transport logistics, and patients’ 
samples, transported and tested without charge,
3. Laboratory capacity building,
4. Training of surveillance officers at the different levels 
of care,
5. Development of Standard Operating Procedures 
(SOP)
6. Rapid response teams provide capacity building and 
support to affected states 4 weeks earlier than in 2017,
7. More treatment centers were created,
8. Ribavirin was available to patients without charge, 
with the media actively advertising this message, 
encouraging patients to seek medical treatment,
9. Improved media attention.
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Building capacity for effective 
emergency preparedness, outbreak 
investigation and response
Poor preparedness for an outbreak is an important 
challenge facing Lassa Fever prevention and control. It 
is thus important to build early warning indicators and 
rapid response to adequately prevent or respond to Lassa 
fever. A list of required medicines and supplies to prepare 
for an outbreak should be made accessible (WHO/NCDC, 
2013; NCDC, 2017).
Accelerating research and development to bridge 
the gaps in diagnosis, environmental transmission, 
treatment and diagnosis through data collection.
In order to achieve this, there is a need to identify and 
fund key research priorities in Lassa Fever prevention, 
to cover strain variation, cross contamination, vaccine 
development, biological behaviour of the viral agents and 
its activity in rodent host, person to person transmission, 
rodent distribution and control, surveillance, 
environmental factors and biting behaviour of the vector.
5. Conclusion
Epidemics of emerging and re-emerging infectious 
diseases are on the increase, with devastating health, 
social and economic consequences. Lassa fever as a 
prototype is a preventable and treatable disease that is 
currently ravaging Nigeria and the West African sub-
region, with a single case of Lassa Fever regarded as an 
outbreak. Despite measures to prevent and control the 
spread of Lassa virus (LASV), the fight against Lassa Fever 
is hampered by several challenges relating to diagnosis, 
poor knowledge risk perception and preventive practices 
among community members and health care workers, 
poor treatments and general prevention. The efforts to 
curtail Lassa Fever would yield significant reduction 
in prevalence if these challenges militating against 
prevention and control are removed. This would require 
collaborative efforts among all stakeholders that are 
relevant to this task, and Governments creating an 
enabling environment for prevention and control efforts 
to thrive.
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